Luca Pinello
- Enhancer work underpinning Casgevy, the first FDA-approved CRISPR therapy
- Corresponding author, DNA-Diffusion (Nature Genetics 2026)
- Co-founder of Edilytics
- NIH NHGRI Genomic Innovator Award
Synthetic regulatory DNA
Precise gene control for better therapies.
Every gene therapy depends on regulatory DNA to switch its gene on in the right cells, at the right level. Locium designs and validates synthetic regulatory elements that do exactly that, so treatments can be safer, more effective and reach more patients.
Regulatory activity
Illustrative
01Platform
Map, design, validate. One team, end to end.
01Map
Regulatory atlases
Reference maps of regulatory DNA activity across the human body reveal the grammar that makes an element specific.
02Design
Generative models
AI models trained on that grammar write entirely new sequences, engineered for a defined pattern and level of activity.
03Validate
Measurement at scale
Massively parallel reporter assays test hundreds of thousands of designs at once, in cells and in vivo.
Every experiment feeds back into the atlas and the models, so each design cycle improves on the last.
Why Locium
Others specialize in one step: computational design without experimental proof, or screening without generative design. Locium brings mapping, design and validation together in a single closed loop.
02Founders
Three laboratories, one platform. Each founder built a cornerstone of the field. Together they cover every step.
Steven Reilly
- Co-led CODA, machine-guided regulatory element design (Nature 2024)
- Noncoding CRISPRi screens (Nature Methods 2024)
- 2025 Pew Biomedical Scholar
- Member, NHGRI IGVF Consortium
Wouter Meuleman
- Led the human regulatory DNA reference atlas (Nature 2020)
- Co-led the NIH Roadmap Epigenomics integrative analysis (Nature 2015)
- Co-originator of DNA-Diffusion
- NIH NHGRI Genomic Innovator Award
03Contact
Let’s talk.
We work with partners who need precise control over gene expression. Whether you are exploring a collaboration, a partnership or an investment, we would like to hear from you.